Ripple Therapeutics Appoints Jonathan Talamo, M.D., to Board of Directors

TORONTO, ON, CANADA / ACCESSWIRE / MAY 4, 2021 - Ripple Therapeutics Corporation (“Ripple”) a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, is pleased to announce the appointment of Jonathan Talamo, M.D., to the Board of Directors.  Dr. Talamo is internationally known as an ophthalmologist, innovator and consultant to industry with more than 25 years of experience in healthcare.  

Dr. Talamo is the former Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. Prior to that, he served as the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug delivery company, where he oversaw clinical development programs in multiple therapeutic areas, including post–cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases.


“As a long-time practicing Ophthalmologist who has also worked in industry to develop extended-release ophthalmic medications, I know there are huge unmet needs for patients across multiple disease states”, commented Dr. Talamo. “I’m really excited to work with the Ripple team to bring first-in-class proprietary extended-release ophthalmic therapeutics to market.”


“We are extremely pleased to have Dr. Talamo join our Board of Directors”, stated Tom Reeves, President and CEO, Ripple Therapeutics.  “He brings a unique combination of clinical expertise as a practicing ophthalmologist and industry experience with both large and small companies.  He will be a great asset for Ripple as we look to realize on our vision of providing safe and effective treatment options for patients with sight-threatening conditions.”


About Ripple Therapeutics:

Ripple Therapeutics Corporation is a clinical stage privately held company that is focused on improving ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel technology is the ability to engineer drugs into materials with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development. www.rippletherapeutics.com

 

Media Contact:

Julie Fotheringham, V.P. Marketing, People & Culture

RIPPLE-ABBVIE OPHTHALMIC DRUG DELIVERY PANEL

February 12, 2026
Our Chief Technology Officer, Wendy Naimark , was pleased to be speaking with AbbVie Directors, Allison Hoch, PhD, MBA, Director of Global Alliances and Amy Hopkin Director of Search & Evaluation for AbbVie Eyecare, on a Harnessing Innovation & Collaboration to Accelerate Ophthalmic Drug Delivery Panel at the 4th Annual Ophthalmic Drug Delivery Summit on Thursday January 29th in San Francisco, CA. 🗣️ Topic: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact. Areas Covered: ✅ Co-developing platforms, managing device timelines and regulatory alignment in combo products ✅ Leveraging the speed and innovation of biotech startups with deep experience and resources of pharma ✅ Continuous learning through cooperation during diligence, development planning and execution phases ✅ The importance of proactive, transparent communication across functions to anticipate challenges and optimize for success View Presentation

Ripple Therapeutics Enters Collaboration with Bausch + Lomb

November 25, 2025
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.